​

According to Animal Health and Surveillance Act No. 5699, Anthrax is a notifiable zoonotic disease.

In our country, Pasteur vaccine was the first vaccine to be used against Anthrax in 1910; followed byTurkish Universal Anthrax vaccine of Sureyya Aygun in 1929 andsince1953, a universallyaccepted vaccine developed by Max Sterne and prepared from Bacillus anthracis 34 F₂strain has been used.

Against anthrax disease in cattle, equine, camels, buffaloes, sheep, goats and pigs, ANT ETVAC Anthrax Vaccine is an attenuated bacterial vaccine that consists of 50% v/v glycerol-physiological saline, 0.1-0.025% v/w saponin (depending on titre) and 10⁷/mllive spores.

The vaccine is administered in the spring season in locations presenting a risk of infection, immediately upon disease outbreaks and on disease-free animals for protection purposes. As the disease agent, Bacillus anthracis, is resistant to environmental conditions, vaccinating the animals infected with the disease every year for a period of 5 years is an efficient way of controlling the disease.

Vaccine production output in our institute is 2.000.000 doses per year.The annual production output is determined according to the quotasspecified in the leaflet on the Control Program against Animal Diseases and Pests annually published by the General Directorate of Food and Control under the Ministry of Food, Agriculture and Livestock.

A. DUTIES

ANTHRAX VACCINE PRODUCTION:The master seed strain is Int.Std.Anthrax Max Sterne 34 F₂ PA0522 lyophilised strain that is provided from Veterinary Laboratories Agency (VLA)-Weybridge designated as the Reference laboratory by World Health Organization. This strain is lyophilised at the recommended media. After purity and antigenic controls, it is kept under -20⁰C. Vaccine production is performedin the Casein Digest medium. Sterility, immunity and innocuity controls are conducted in conformity with O.I.E., European Pharmacopoeia and WHO.